Introduction
Protein misfolding, phosphorylation, and aggregation are central features of many neurodegenerative diseases
These pathogenic proteins can seed further misfolding and propagate pathology across anatomically connected brain regions
These processes contribute to cellular dysfunction and death, and are increasingly being targeted by novel therapeutics in the drug discovery landscape
MDC has developed human in vitro systems to study the pathology of α-synuclein and tau in iPSC-derived cortical neurons in 96- and 384-well format using high content imaging assays and analysis pipelines
View the poster here
New appointments support MDC’s mission to turn drug discovery into commercial breakthroughs.
Dr Emma Jones, a Lead Scientist in in vitro Neurobiology at Medicines Discovery Catapult (MDC), has contributed to a new children’s book celebrating the diversity of careers in science.
Investment and expert support will help accelerate the development of new treatments for a range of autoimmune, inflammatory, and age-related diseases.
